Steatotic Liver Disease (SLD), particularly Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-Related Liver Disease (ALD), is a common chronic liver disease that can progress from simple steatosis to cirrhosis and liver cancer. Because steatotic liver disease often develops without noticeable symptoms, early diagnosis and risk assessment remain challenging, while disease progression and treatment response vary between individuals.

By combining clinical, lifestyle, imaging and molecular data, AIRIS will help investigate disease mechanisms, improve risk prediction and support more personalised approaches to prevention and treatment.

Expert teams evaluating AIRIS usability in Steatotic Liver Disease:HUA, LiU, UCL

Cardiovascular Disease encompasses a broad range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and cardiomyopathies. Cardiovascular disease remains a major cause of illness and death worldwide. Their development and progression vary considerably between individuals, reflecting differences in risk factors and underlying biological mechanisms.

Integrating molecular, clinical and other biomedical data will help uncover disease mechanisms and patient-specific patterns, supporting prognostic models and biomarker strategies for improved risk prediction and more personalised interventions.

Expert team evaluating AIRIS usability in Cardiovascular Disease:UKA

Chronic Kidney Disease is a progressive condition in which kidney function gradually declines over time, affecting around 10% of the global population. Because it can progress without noticeable symptoms, the disease may remain undetected until later stages, making early identification of people at risk particularly important.

By integrating diverse biomedical data, AIRIS will help investigate disease mechanisms and progression and support the development of prognostic models and biomarkers to improve risk prediction and enable more personalised prevention, treatment and care.

Expert team evaluating AIRIS usability in Chronic Kidney Disease:UKA

Inflammatory Bowel Disease, including Crohn’s disease, comprises chronic inflammatory conditions of the gastrointestinal tract characterised by periods of active disease and remission. Up to 80% of people with Crohn’s disease require surgery, yet recurrence within five years after surgery remains common, creating challenges for long-term treatment and care.

By integrating clinical and molecular data, AIRIS will investigate factors associated with disease progression and postoperative recurrence, helping identify patients at higher risk and supporting more personalised treatment strategies and long-term care for people living with inflammatory bowel disease.

Expert team evaluating AIRIS usability in Inflammatory Bowel Disease:McGill